Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589

David Z. Qian, Yukihiko Kato, Shabana Shabbeer, Yongfeng Wei, Hendrik M.W. Verheul, Brenda Salumbides, Tolib Sanni, Peter Atadja, Roberto Pili

Research output: Contribution to journalArticle

224 Scopus citations

Abstract

Purpose: Angiogenesis is required for tumor progression and represents a rational target for therapeutic intervention. Histone deacetylase (HDAC) inhibitors have been shown to have activity against various tumor cell types by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. HDAC inhibitors have also been reported to inhibit angiogenesis. The goal of this study was to characterize the antiangiogenic and antitumor activity of a recently developed HDAC inhibitor, the hydroxamic derivative LBH 589. Materials and Methods: To evaluate the antiangiogenesis activity of LBH589, we did cell cycle analysis, cell proliferation, tube formation, invasion assays in vitro, and Matrigel plug assay in vivo. To determine the antitumor activity of LBH 589, we established human prostate carcinoma cell PC-3 xenografts in vivo. To evaluate the effect of LBH589 on endothelial signaling pathways, gene expression, and protein acetylation, we did Western blots and reverse transcription-PCR in human umbilical vein endothelial cells (HUVEC). Immunohistochemical analysis was done to evaluate new blood vessel formation in vivo. Results: LBH589 induced acetylation of histone H3 and α-tubulin protein in HUVECs. Histone and nonhistone protein acetylation correlated with induction of G2-M cell cycle arrest, inhibition of HUVEC proliferation, and viability. Noncytotoxic concentrations of LBH589 inhibited endothelial tube formation, Matrigel invasion, AKT, extracellular signal-regulated kinase 1/2 phosphorylation, and chemokine receptor CXCR4 expression. In vivo dosing of mice with LBH589 (10 mg/kg/d) reduced angiogenesis and PC-3 tumor growth. Conclusion: This study provides evidence that LBH589 induces a wide range of effects on endothelial cells that lead to inhibition of tumor angiogenesis. These results support the role of HDAC inhibitors as a therapeutic strategy to target both the tumor and endothelial compartment and warrant the clinical development of these agents in combination with angiogenesis inhibitors.

Original languageEnglish (US)
Pages (from-to)634-642
Number of pages9
JournalClinical Cancer Research
Volume12
Issue number2
DOIs
StatePublished - Jan 15 2006
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589'. Together they form a unique fingerprint.

  • Cite this

    Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B., Sanni, T., Atadja, P., & Pili, R. (2006). Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clinical Cancer Research, 12(2), 634-642. https://doi.org/10.1158/1078-0432.CCR-05-1132